RNA intelligence for precision oncology

Billion-dollar clinical trial decisions are still made with limited insight into each patient’s underlying biology, leading to expensive failures. Today, we often rely on crude proxies of biology and the same biomarkers to answer critical questions like which patients will respond to a therapy and how their disease will progress.

At the same time, bulk RNA-seq is rapidly gaining adoption in clinical care and drug development. We believe this creates a unique opportunity: a clinically accessible assay that can capture rich biological information at scale. We’re starting to generate more bulk RNA-seq data than we know how to fully interpret. Every sample contains a rich snapshot of disease biology, but much of that information is still unused in practice.

Blank Bio is an applied AI research lab building models that help make sense of that data. We train RNA foundation models to learn patterns linked to disease progression and treatment response. Our goal is to help pharma companies make better clinical development decisions, design smaller and more efficient trials, and increase the odds that promising therapies succeed.

We are currently focused on developing two core applications:

• — Disease trajectory modeling. We predict how a patient’s disease is likely to progress over time using their molecular profile. Through covariate adjustment, these RNA prognostic scores can help clinical development teams design trials that reach statistical power with fewer patients.
• — Patient selection. We help pharma teams understand the biological differences between patients, so they can identify who is most likely to respond to a given therapy. These same signals can also identify emerging resistance mechanisms and potential combination strategies.